A new study is linking personalized bio markers to antidepressant effectiveness. This is another step towards ending the trial and error approach to prescribing antidepressants.
“The future of psychiatry is in a precision, personalized medicine approach to refining diagnosis and tailoring treatments accordingly. This study demonstrates that currently available markers are poised to improve patient outcomes without introducing new costs. Markers such as BMI are likely to complement others being developed out of neuroimaging and genomics,” added Dr. Williams.
Read the full story here